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MJA Practice Essentials – Paediatrics
The distinction between atopy and atopic disease is
child with atopy produces specific IgE antibodies afte
common environmental allergens and is said to be
that allergen. The presence of specific IgE antibodie
by means of a skin prick est or r dioallergosorbent te
Eczema, asthma and rhinoconjunctivitis are clinic
each defined by a collection of symptoms and s298 MJA • Volume 182 NumABSTRACT
• A child with atopy produces IgE antibodies after exposure 
to common environmental allergens. The atopic diseases 
(eczema, asthma and rhinoconjunctivitis) are clinical 
syndromes each defined by a group of symptoms and signs.
• Not all children with atopy will have atopic disease or develop 
symptoms after exposure to an allergen. Both genetic and 
environmental factors determine the development of atopic 
disease.
• The presence of specific IgE antibodies to environmental 
allergens is determined with skin prick or radioallergosorbent 
testing in children with atopy. Test results should be 
interpreted in the context of the clinical history and further 
investigations (eg, allergen avoidance or challenge).
• Management of atopic disease is frequently symptomatic, 
but it is important to avoid identified allergen triggers. 
Immunotherapy may be considered in selected school-age 
children with severe rhinoconjunctivitis.
• Preventing atopic disease in high-risk infants and hindering 
progression of disease in children with established disease 
MJA 2005; 182: 298–304
are the areas of active research.Management of atopic disease should extend beyond symptomatic treatment to identification and 
avoidance of allergen triggers and, if appropriate, immunotherapyhe
vit
affT  atopic diseases — eczema, asthma and rhinoconjuncti-is  — are the commonest chronic diseases of childhood,ecting one in four Australian children. For most children
the symptoms are mild, but those with severe disease are signifi-
cantly disabled. During the past decade, our understanding of the
basic immunology of these diseases has advanced, and this is now
beginning to be translated into more effective preventive and
management measures.








commonly referred to as the atopic diseases. While most children
with these conditions are atopic, some are not, and, conversely,
some children with atopy may not manifest atopic disease.
Development of atopic disease
Atopic disease occurs when the immune system is dysregulated,
resulting in allergic inflammation. Genetic and environmental
factors determine the dysregulation and the development of an
atopic disease.
Genetic factors
Atopic disease has a strong hereditary component — if both
parents are affected by an atopic disease (or one parent and a
sibling) 40% of offspring will be affected. The genetic influence is
multifactorial — no single atopy gene has been identified. It is
likely that children who have inherited the “atopy gene(s)” are
more likely to become sensitised and to develop allergic inflamma-
tion when exposed to the specific environmental influences.1,2
Environmental factors
Environment is an important determinant of atopic disease. Evi-
dence for this includes the regional differences in disease inci-
dence, the recent increase in prevalence of atopic disease, and that
children born in a “low atopy” country tend to develop the atopic
disease patterns of their host country when they migrate to a “high
atopy” country.3
When do environmental factors exert their major effects? There
may be a “window of opportunity” in the first few years of life
when the developing immune system is particularly susceptible to
being directed along an atopic pathway. However, given that adults
who migrate can manifest atopic disease after a change in environ-
ment, immune changes may also occur at an older age.
Determining which environmental factors prevent or promote
atopic disease is complex (Box 1). A credible suggestion for the
environmental effects is the “hygiene hypothesis”, which postu-
lates that reduced exposure to infectious diseases and microbial
products (endotoxin), associated with a “cleaner” lifestyle in
urbanised communities, has lessened the immune deviation of the
developing immune system to a non-allergic response.4-6 Previ-
ously, allergen exposure was thought to be the most important
environmental factor influencing this immune deviation. However,
the role of allergen exposure in the development of atopic disease
is yet to be clearly defined. For example, the “dose” of allergen
exposure may be critical — early exposure to high levels of cat
allergen may protect against the development of asthma, whileber 6 • 21 March 2005
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of the factors that promote or prevent the development of atopic
disease is needed, so that primary prevention interventions appli-
cable to communities can be recommended.
Prevalence
The International Study of Asthma and Allergies in Childhood
showed that there was marked variation in the global prevalence of
atopic disease.3 This variation occurs not only between countries
but also regionally within countries, with the highest prevalence
being in westernised, industrialised countries. In these countries
the prevalence of atopic disease has been rising since the latter part
of the 20th century. Australian and New Zealand children have the
fifth highest global rates of atopic disease (Box 2). Interestingly,
recent Australian data in children suggest that the prevalence of
asthma has plateaued, while that of eczema and rhinoconjunctivi-
tis continues to increase.8
Diagnosis
The first atopic disease to manifest is eczema, which usually
commences in early infancy. For up to 40% of children with
eczema there is progression to asthma and/or rhinoconjunctivitis,
and most develop respiratory symptoms before 5 years of age. This
progression in atopic disease is termed the “atopic march”.
There is seldom difficulty in diagnosing atopic diseases. The
essential features of the three diseases are:
• Eczema — pruritus, the typical appearance and distribution of
the rash, and the chronic relapsing course. Important associated
features include xerosis, atopy, a family history of eczema, kerato-
sis pilaris, and atypical vascular skin responses.
• Asthma — symptoms and signs of intrathoracic airway tract
obstruction triggered by specific factors (exercise, viral infection,
allergen exposure) and relieved by bronchodilators.
• Rhinoconjunctivitis — rhinorrhoea, sneezing, nasal and eye
itch and nasal congestion. When symptoms occur seasonally the
cause is likely to be allergic, but 40% of children have perennial
symptoms, and non-allergic causes need to be considered in the
differential diagnosis.
Investigations
Children with atopic disease are frequently tested by means of a
skin prick test or RAST to determine the presence of IgE antibodies
specific to common environmental allergens. The indications for
performing these tests are given in Box 3. The tests can answer the
question “Does this patient have IgE antibodies to a particular
allergen of interest?”. However, they do not necessarily answer the
question “Is this allergen a cause of the patient’s symptoms?”. This
is because positive results of skin prick tests and RAST frequently
occur in asymptomatic subjects. To answer the second question,
the results of the test have to be assessed together with the clinical
history, and, in certain circumstances, in conjunction with either
allergen reduction (eg, a trial of dust mite avoidance measures) or
allergen challenge.9,10 However, a negative result of a skin prick
test or RAST usually excludes the presence of an IgE-mediated
allergy trigger (Box 4).
Skin prick testing (Box 5) can be done in children of any age,
and it is a misconception that the test is less reliable or cannot be
interpreted in toddlers and infants. Skin prick test results are given
as the mean weal diameter (in mm) measured at 15 minutes. A
skin prick test is positive if the weal diameter is 3 mm or greater in
the presence of a negative control. When referring patients for skin
prick testing, it is important to instruct them not to take antihista-
mine medication, as this will interfere with the test results. Steroids
and β-agonists do not interfere with a skin prick test. Skin prick
testing should only be performed by practitioners who have been
trained in performing the test and interpreting the results.
RAST, which measures IgE antibody levels in serum, provides
similar information to a skin prick test, but may be less sensitive or
specific than a skin prick test (which is a measure of the actual
reaction to the allergen including mediator release from mast
cells), but it is more widely available and can be performed even if
3 Indications for determining specific IgE antibodies (by 
skin prick test or RAST) in atopic disease
Eczema
• When house dust mite allergy is suspected as a trigger
• When IgE-mediated food allergy is suspected, either as a trigger 
or an associated condition
Asthma
• When determining the atopic status is important to support the 
diagnosis of asthma
Rhinoconjunctivitis
• When house dust mite allergy is suspected as a trigger for 
perennial rhinitis
• When determining the atopic status is important to support the 
diagnosis of allergic rhinoconjunctivitis
• When immunotherapy is being considered, specific IgE 
determination is used to identify the allergen
2 Prevalence of atopic disorders among Australian 
children
Prevalence of: 6–7 year olds 13–14 year olds
Eczema ever (current eczema) 23% (11%) 16% (10%)
Asthma ever (current wheeze) 27% (25%) 28% (29%)
Hayfever ever (current rhinitis) 18% (12%) 43% (20%)
Data obtained from the International Study of Asthma and Allergy in 
Childhood (questionnaire-based survey of 10 914 children in Melbourne, 
Sydney, Adelaide and Perth).1
1 Perinatal and early childhood factors associated with 
preventing or promoting atopic disease
Factors preventing Factors promoting 
• Allergen exposure* • Parental smoking
• Omega-3 fatty acid intake • Use of antibiotics
• Endotoxin exposure • Allergen exposure*
• Frequent infections
• Prolonged breastfeeding
• Delayed introduction of 
solids
• Probiotics
* See text for explanation.MJA • Volume 182 Number 6 • 21 March 2005 299
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semiquantitative measure (low–moderate–high) or preferably as a
level of specific IgE (IU/L).
In some children with atopy, skin prick testing and RAST are
used to aid in the diagnosis of an IgE-mediated food allergy. There
are published data for a restricted range of foods (egg, nuts, milk,
soy, fish and wheat), correlating the level of specific IgE to the
probability of a child reacting to that food;11,12 a particular form of
RAST (CAP-RAST; Pharmacia, Michigan, USA), as well as skin
prick testing, has been used (Box 6). If the weal diameter (usually
> 6 mm) or RAST IgE level is above a predetermined cutoff, the
child will have a greater than 95% probability of reacting to a
formal food challenge. The level of specific IgE to a food allergen is
best used together with the clinical history in the diagnosis of IgE-
mediated food allergy. Specific IgE level can also be used as an
indication of whether to perform a food challenge in children with
a history of food allergy. Tests in children with non-IgE-mediated
food allergy and food intolerances will not show the presence of
specific IgE.
Principles of management of the atopic diseases
Currently, there are no known interventions that can cure allergic
inflammation, and management is frequently symptomatic.
However, it is important, if possible, to identify and avoid
allergen triggers — in some circumstances this may allow for
more effective symptomatic treatment. In specific circumstances,
immunotherapy has a place for children older than 7 or 8 years
of age with significant allergic rhinoconjunctivitis (see section on
Immunotherapy, page 301).
Identification and avoidance of allergens
Although atopic disease is commonly exacerbated by non-allergen
triggers (eg, viral infection in asthma, skin irritants in eczema),
identification and avoidance of potential allergens may signifi-
cantly improve the disease.
Ingested allergens
Eczema is a major risk factor for food allergy.13 About 40% of infants
with eczema will be sensitised to common food allergens, and a
significant number of these will have a clinical food allergy. Food
allergy should be suspected in infants with eczema who have:
• severe eczema with a poor response to topical treatment;
• recurrent vomiting — may be misdiagnosed as gastro-oesopha-
geal reflux;
• loose stools and failure to thrive;
• a family history of food allergy; and
• episodes of urticaria or anaphylaxis.
Exposure to allergens in food, or possibly breastmilk (Box 7),
may exacerbate eczema.14 Food allergens (eg, ovalbumin, casein,
nut) have been detected in breastmilk after maternal ingestion.15
Ingested allergens do not cause asthma or rhinoconjunctivitis, but
acute wheeze or nasal symptoms may occur as part of a generalised
allergic reaction.
Most food allergies in children are triggered by cow’s milk, egg,
nut, sesame seed, soy, wheat and seafood proteins. These foods are
basic components of children’s diets, so empirical avoidance is not
recommended, as this may have adverse nutritional consequences,
particularly in young children. Avoidance should only occur after a
complete assessment to identify food allergies.
Once a food allergy has been identified, avoidance is the best
treatment. However, avoiding food allergens can be difficult given
their ubiquitous presence in foods, confusing food labelling, and
hidden sources. Ideally, parents should consult a dietitian, who can
educate them about avoiding food allergens and ensure that the
child’s diet remains nutritionally adequate. This is particularly
important for children with a cow’s milk allergy to maintain their
calcium intake.
Inhaled allergens
Children are constantly exposed to various aeroallergens, depend-
ing on geographic, climatic and local factors. The principal indoor
allergens are house dust mite, animal dander and cockroach, while
outdoor allergens include pollen (grass, tree, weed) and moulds.
Measures to reduce exposure to indoor allergens are more effective
than those to reduce exposure to outdoor allergens. Several
5 Skin prick testing
A skin prick test, showing multiple weal and flare reactions to 
common allergens in an atopic child with eczema.
4 Uses of skin prick tests (SPT) and radioallergosorbent 
testing (RAST)
Things SPT/RAST can tell us
• That a patient is sensitised to an allergen
• The likelihood of reacting after a food challenge (restricted range 
of foods)
• That a patient is not sensitised to an allergen and therefore an 
IgE-mediated reaction to that allergen is very unlikely
Things SPT/RAST cannot tell us
• The severity of a reaction if a sensitised patient were exposed
• Whether the patient’s symptoms are caused by the allergen300 MJA • Volume 182 Number 6 • 21 March 2005
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ing animal dander exposure can be achieved by removing pets
from households, but this seldom occurs. Outdoor allergens
cannot be effectively avoided.
Measures to reduce exposure to house dust mites have not been
shown to be effective in improving symptoms of asthma,17 but
may be of benefit in rhinoconjunctivitis or eczema,18,19 although
the results of studies have not been consistent.
Symptomatic treatment
Symptomatic treatment is indicated when there are unidentified
allergen triggers, or allergen avoidance is impossible or results in
only a partial response. The medications used are either anti-
inflammatory and/or designed to block the effects of mediators
released during the allergic or atopic response. The anti-inflamma-
tory action of topical, inhaled, and sometimes oral, steroids is a
mainstay of treatment. The recent development of leukotriene
antagonists (montelukast) for use in mild persistent asthma, topical
calcineurin inhibitors for eczema (tacrolimus and pimecrolimus),
and monoclonal anti-IgE antibodies for asthma provide non-steroi-
dal anti-inflammatory alternatives. In the future, other biological
agents (such as monoclonal anti-IgE antibodies) will become availa-
ble and offer an approach without associated side effects.
Unfortunately, there are a small number of children who, despite
anti-inflammatory medication, have severe and disabling atopic
disease. For children with severe eczema, oral immunosuppressive
treatment may be indicated, and there are published case series and
placebo-controlled studies on the use of cyclosporin and azathio-
prine.20,21 As mentioned previously, immunotherapy should be
considered for older children with severe rhinoconjunctivitis.
Immunotherapy
The process of administering gradually increasing quantities of an
allergen extract to induce tolerance was first used for grass-pollen-
induced allergic rhinitis almost 100 years ago. Immunotherapy is
only effective for IgE-mediated inhalant allergic disease and,
although the exact mechanism is not known, immunotherapy is
associated with the production of blocking antibodies, downregu-
lation of lymphocytes and a decrease in allergen-specific IgE.
There is evidence from numerous randomised controlled trials
for the efficacy of injectable specific immunotherapy in rhinocon-
junctivitis and/or asthma.23,24 The allergens evaluated include
house dust mite, cat, and grass pollens, and there is limited
evidence for some weed and tree pollens and moulds. As few trials
have been conducted in children, injectable immunotherapy
should only be done in school-age children with intractable
rhinoconjunctivitis, and it is not recommended for treating asthma
or in preschool children.
There is growing evidence that immunotherapy by other routes,
particularly sublingual, provides some clinical benefits in selected
subjects.25 However, the magnitude and duration of the effects, the
benefit for asthma, and the effects on the underlying immunologi-
cal mechanisms remain to be determined. Nevertheless, this route
has obvious benefits for children and further research is awaited.
6 Specific IgE level related to the 
probability of a food reaction
Food-specific IgE level (measured by 
ImmunoCAP-specific IgE blood test) and 












7 Eczema in a 4-month-old infant
A: A 4-month-old boy with extensive eczema responded poorly to topical treatment, 
including corticosteroids. Exclusively breast fed, he had not yet commenced solids. Skin prick 
testing produced an 8-mm weal to egg protein and a 6-mm weal to cow’s milk protein, but 
was negative for peanut, wheat, soy and fish. Topical treatments were continued, and egg 
and cow’s milk were excluded from his mother’s diet under dietetic supervision. B: Child’s 
appearance 6 weeks later.
8 Measures to reduce house dust mite allergen exposure
Definitely useful
• Encasing bedding in impermeable covers (dust mite covers) (this 
is the most important measure, as beds are a major source of 
house dust mite)
• Washing bedding and clothes in hot water (> 56°C) every 1–2 
weeks, which will destroy house dust mites and remove allergens
• Removing or freezing stuffed toys
• Reducing indoor relative humidity
Unlikely to be useful
• Spraying carpets and mattresses with acaricides (dust mite sprays)
• Washing of bedding in cold water with tea tree oilMJA • Volume 182 Number 6 • 21 March 2005 301
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therapy should be initiated and supervised by an allergist.26 Safety is
a major concern. While injection-site reactions are common, sys-
temic reactions are uncommon, but may result in bronchospasm
and/or anaphylaxis, including hypotension, upper-airway oedema
and collapse. Rarely, death may result, with most cases involving
individuals with asthma, the use of highly purified and potent
aqueous extracts and divergence from recommended protocols.
Important associated conditions complicating atopic 
disease
A number of conditions complicate atopic disease and these should
be considered when evaluating a child with atopy. For example, food
allergy, or bacterial or viral skin infection (eg, eczema herpeticum or
molluscum contagiosum) may complicate eczema, and obstructive
sleep apnoea may complicate allergic rhinitis.
Food allergy and anaphylaxis
Many children with IgE and non-IgE-mediated food allergy have
eczema. In addition, about a third of infants and young children
with moderate to severe atopic eczema have been shown to have
food-related triggers for their eczema. Several factors have been
identified that suggest the occurrence of food allergy in infants and
children with eczema (see list under the heading Ingested aller-
gens on page 300).
Food allergy may be caused by the presence of specific IgE
antibodies (in which case children have immediate reactions) or
may be non-IgE (possibly T lymphocytes)-mediated reactions
(which may exacerbate the eczema in a delayed fashion). The latter
reactions can occur in the presence of a negative skin prick test or
RAST to the exacerbating food.
Anaphylaxis is a severe and rapidly progressive generalised
allergic reaction with multisystem involvement, including the
respiratory and/or cardiovascular system. About 1 in 166 Austral-
ian school-aged children have experienced an episode of anaphy-
laxis, with the most common trigger being food, followed by insect
venom, and, uncommonly, drugs.27 Atopic disease is not a risk
factor for anaphylaxis triggered by drugs or insect venoms.
However, food anaphylaxis is more common in children with
eczema. Children with asthma are more likely to have severe
episodes of anaphylaxis, regardless of the trigger. Death in child-
Case studies
A 19-month-old boy with food allergy
A mother brings her 19-month-old son to you after an allergic reaction. 
He has a history of eczema at 2 months of age. Subsequently, his mother 
avoided introducing egg and peanut products, as she had read they 
were bad for the eczema. She has given him wheat-containing foods with 
no exacerbation of the eczema. At 18 months of age, skin contact with 
raw egg white (hands and transferred to mouth) resulted in urticaria at 
the sites of contact that then became generalised and was associated 
with respiratory difficulty and wheeze. An ambulance was called and he 
was given inhaled bronchodilator, but he was not taken to hospital and 
adrenaline was not used.
Examination shows a healthy boy weighing 11 kg who has mild eczema. 
On skin prick testing, there is a positive reaction to egg white (10-mm 
weal), peanut (4-mm weal), and wheat (4-mm weal) but a negative 
reaction to cow’s milk.
Management
• You explain to the mother that her son has an (IgE-mediated) 
allergy to egg, and that the generalised nature of his reaction to 
raw egg suggests he has ingested egg allergen. In view of the 
significant respiratory difficulty he experienced and his weight 
(> 10 kg), you provide the mother with an EpiPen Jr (150 µg) (CSL, 
Melbourne) and a written anaphylaxis action plan. You explain that 
an acute allergic reaction to food with respiratory difficulty is best 
treated with adrenaline.
• The mother is sure that her son has never eaten peanut or peanut 
products, so you cannot be certain that he has peanut allergy. You 
explain that it is not uncommon for children with eczema and egg 
allergy to be sensitised to peanut without known ingestion, as 
exposure may have occurred via breast milk.
• You reassure the mother that children often grow out of milk and 
egg allergy by 5 years of age (but this is less likely for peanut 
allergy). You arrange to reassess the boy yearly, with repeat skin 
prick testing to see whether he is growing out of any of the allergies. 
You suggest that he continue to eat wheat products, despite the 
positive skin prick test, as no clinical reaction to wheat has occurred. 
You advise continued avoidance of peanut products, and, if 
sensitisation persists, recommend that he have a peanut challenge 
test in hospital before school entry.
An 8-year-old boy with chronic rhinitis
A mother brings her 8-year-old son to you because of worsening snoring 
and difficulty breathing at night. He has a history of rhinorrhoea, nasal 
itch, and snoring from 4 years of age. She tells you that his symptoms 
have been progressing and that he now snores every night, affecting his 
sleep. She has become concerned about his difficult breathing and 
interrupted sleep. Although his symptoms occur all year round, they are 
worse in spring. He has been treated intermittently with promethazine 
and topical nasal steroids, with little effect. His teachers complain that 
he seems unable to concentrate at school. He does not have asthma, 
but has a history of eczema. The family has no pets and neither parent 
smokes. His mother has sought naturopathic advice, and he has 
undergone a Vega test,22 and now cow’s milk and wheat have been 
excluded from his diet.
Examination shows that he has a nasal crease, bilateral pallor, swelling 
of the inferior nasal turbinate bones and that he breathes through his 
mouth. On skin prick testing, he reacts to a rye grass pollen and house 
dust mite mix (10-mm weal). Skin prick testing is negative for common 
moulds and animal dander.
Management
• You explain to the boy and his mother that he has symptoms of 
chronic rhinitis, which is likely to be allergic and triggered by 
exposure to seasonal pollen allergens and/or house dust mite.
You recommend trying allergen avoidance measures for house 
dust mite (see Box 8) to see if he responds (indicating that he 
has a house dust mite allergy).
• Seasonal allergens are harder to avoid and you recommend 
consistent symptomatic treatment with nasal corticosteroids, rather 
than oral antihistamines, for his symptoms of nasal obstruction. You 
suggest continuous treatment for at least 2 weeks.
• If, despite treatment, snoring continues, you recommend an x-ray 
of his posterior nasal space to exclude adenoidal hypertrophy, and 
possibly investigation for obstructive sleep apnoea.
• If, despite allergen avoidance and symptomatic treatment, 
intractable symptoms persist, you refer the boy to an allergist to 
institute and supervise immunotherapy, using rye grass and house 
dust mite extracts. As he does not have asthma, the risk of a 
serious adverse reaction is reduced.302 MJA • Volume 182 Number 6 • 21 March 2005
MJA PRACTICE ESSENTIALS –  PAEDIATRICShood from anaphylaxis is a rare event, but is clustered in
individuals with asthma.
The primary treatment of anaphylaxis is adrenaline, which can
safely be administered intramuscularly in all children.28 Children
with anaphylaxis should have an EpiPen, and should know how to
avoid the trigger (if identified). They should be referred to an
allergist for review. Australian guidelines for EpiPen prescribing
have been published (www.allergy.org.au/anaphylaxis/epipen_
gu ide l ines.htm) ,  a s have  anaphylax is  ac tion plans
(www.allergy.org.au/aer/infobulletins/posters/Anaphylaxis_plan_
(child)_Au.pdf). An EpiPen should only be prescribed in the
context of an anaphylaxis action and management plan, which
must include education on its correct use. EpiPens have recently
become available through the Pharmaceutical Benefits Scheme via
authority prescription (see www.health.gov.au/pbs/general/listing/
pbacrec/jun03/adrenali.htm).
Education of teachers and other school staff in anaphylaxis
prevention and management is important and is included in the
first-aid training programs conducted in many states.
Allergy prevention
As a result of the complexities surrounding environmental influ-
ences, including which potential parents should be targeted, it is
not possible to make definitive recommendations on allergen
avoidance to prevent atopic disease. Currently, the following
factors play a role:
• Breastfeeding: Exclusive breastfeeding for 4–6 months exerts
some protective effect.29 This protection may persist for at least the
first decade of life. However, the protective effects are relatively
modest and have not been confirmed by all studies. Breastfeeding
might reduce atopic disease by favouring the development of gut
flora populations of bifidobacteria and lactobacilli, which appear
to be protective.30
• Solid food: Introduction of all solids should be delayed until
after the age of 6 months, and the more highly allergenic foods —
egg, peanuts, tree nuts, and fish — can be delayed for 2–3 years to
lessen eczema and food allergy. It seems clear that the beneficial
effects of delaying solids are restricted to the first few years of life,
and that there is no significant benefit observed by the school-age
years.
• Fish oils: Observational studies show that one of the strongest
protective factors for respiratory symptoms in children is inclusion
of oily fish (which have a high content of omega-3 fatty acids) in
the diet.31,32 A recent trial of dietary fish oil supplementation from
birth showed a significant reduction in allergic cough, but not
wheeze, at 3 years of age.
• Smoking: Parents should refrain from smoking, as smoking
increases the risk of recurrent wheeze and asthma.
Research is being conducted into ways of preventing asthma in
atopic children with eczema. Interventions under investigation
include pharmacological measures such as the regular use of a
non-sedating antihistamine, allergen avoidance, dietary interven-
tions and immunotherapy. Results are awaited with interest and, if
effective, such interventions may have significant public health
benefits.
Conclusion
It is fortunate that the recent increasing prevalence of atopic
disease has coincided with an improved understanding of the basic
pathogenic mechanism of these conditions. With time, this should
allow more effective preventive and management strategies to be
developed. Management of children with atopic disease should not
be confined to symptomatic treatment, but should extend to
identification and avoidance of allergen triggers and, if appropri-
ate, immunotherapy. Prevention of atopic disease in high-risk
infants and prevention of asthma in children with eczema are areas
of current research.
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